Know Cancer

or
forgot password

Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study


N/A
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study


Inclusion Criteria:



- patients > 18 years of age with primary lung, esophageal or rectal cancer receiving
neo-adjuvant chemoradiotherapy before planned resection

- patients with clinically localized prostate cancer receiving definitive radiation
therapy with external beam treatment. brachytherapy as a boost and/or hormonal
therapy are allowed.

- patients with head and neck, lung, esophageal or cervical cancer who will receive
definitive radiotherapy

Exclusion Criteria:

- prior history of chemotherapy given within 6 months before enrollment.

- prior radiotherapy or radionuclide treatment and/or brachytherapy within 6 months
prior to enrollment.

- unwillingness to comply with tests, protocol, or informed consent.

- concurrent enrollment on any protocol that would require non-compliance with
treatment procedures.

- chemotherapy required within 2 hours following first dose of XRT.

- PET scan done within 48 hours of first blood draw.

- nuclear medicine exposure within 4 days prior to first draw.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

Kas R Badiozamani, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Virginia Mason Hospital/Medical Center

Authority:

United States: Institutional Review Board

Study ID:

IRB09016

NCT ID:

NCT01050725

Start Date:

November 2009

Completion Date:

Related Keywords:

  • Cancer
  • proteome
  • biomarkers
  • radiotherapy
  • cancer

Name

Location

Virginia Mason Medical CenterSeattle, Washington  98111